Vertex Pharmaceuticals Inc (NAS:VRTX)
$ 465.73 -2.4 (-0.51%) Market Cap: 119.94 Bil Enterprise Value: 115.74 Bil PE Ratio: 0 PB Ratio: 7.68 GF Score: 93/100

Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 07:30PM GMT
Release Date Price: $226.49 (-1.07%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning, everyone. My name is Cory Kasimov. I'm the senior large-cap biotech analyst at JPMorgan, and it's my pleasure to be hosting the next session here. And instead of a standard presentation, we're doing a little fireside chat without the fire. And doing it -- it's really a pleasure to be doing this with Vertex. And it's a good time to be doing it with the transition that's taking place between Jeff and Reshma. But -- so we'll go through a list of questions here. I may also remind everybody that we are not having a breakout session. So this is in lieu of a breakout session, just to make sure no one is running to the room across the hall and fighting the lunch crowd.

And with that, maybe I'll turn it over first to Jeff to make some introductory remarks.

Jeffrey Marc Leiden
Vertex Pharmaceuticals Incorporated - Chairman, CEO & President

Yes. Thank you, Cory. It's always good to start our year here at JPMorgan with you. It's sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot